ADVA
15.9.2022 09:01:51 CEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its AccessWave25™, empowering network operators to easily migrate their 10Gbit/s access infrastructure to 25Gbit/s connectivity without a significant increase in footprint or major changes to the existing optical layer. The pluggable device answers the urgent need for higher bandwidth services in mobile X-Haul, cable access and wholesale networks. Operators can now slot the AccessWave25™ into any standard-based SFP28 port for an instant capacity upgrade without replacing existing demarcation or aggregation devices. Using patent-pending distance optimization technology, the device also extends 25Gbit/s DWDM reach to 40km, and its G.metro auto-tuning technology reduces provisioning efforts and simplifies operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005787/en/
ADVA’s AccessWave25™ offers an easy route to 25G DWDM connectivity in access networks without any major upgrades. (Photo: Business Wire)
“Our AccessWave25™ is the key to unlocking more bandwidth at the edge. Now network operators have an easy, low-cost way to address soaring bandwidth consumption that doesn’t require extra real estate or cause major disruption to services. And as well as boosting capacity, the AccessWave25™ offers a substantial increase in reach. While today’s solutions can’t go beyond 15km, our new pluggable device uses PAM4 modulation and direct-detection technology to support data transport up to 40km,” said Christoph Glingener, CEO of ADVA. “Simple to deploy and ideally suited for outdoor use, our AccessWave25™ device will be the foundation for the next generation of optical access networks.”
ADVA’s AccessWave25™ plug enables the seamless upgrade of fiber-based access networks. Host-agnostic and with a standardized SFP28 form factor, it empowers operators to instantly connect switches, routers and many other devices to DWDM open line systems. With full C-band tunable interfaces and G.metro self-tuning capabilities, the device reduces set-up time, minimizes human error and delivers operational cost savings. Network operators can also use the G.metro communication channel to remotely monitor the status and health of plugs for easy troubleshooting of any issues. Using less than 3 watts and with an I-temp hardened design, the AccessWave25™ is perfect for deployment in a wide range of outdoor settings.
“The latest addition to our pluggable technology portfolio answers the most urgent needs of our customers in a wide range of industries. From the core to the metro to access networks, our product range offers a plug for almost every situation,” commented Saeid Aramideh, VP of business development at Optical Engines, ADVA. “OurAccessWave25™ is a vital addition to our AccessWave™ family of pluggable devices and features our latest G.metro technology. Either with a third-party OLS or with our turnkey FSP 3000 solution for passive optical access networks, our pluggable technology provides the tools for tackling relentless growth in data consumption as well as the ever-changing demands of optical access networks.”
Further details on the ADVA AccessWave25™ are available in these slides: https://adva.li/accesswave25-slides.
A supporting product video is also available here: https://youtu.be/bcV06nMJ3_c.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005787/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release
Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release
- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release
New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom